Fremont, CA, June 19, 2010 --(PR.com
)-- Plasminogen activator (PA), classified immunological into urokinase-type PA (uPA) and tissue-type PA (tPA), converts the zymogen plasminogen to the active, broad-spectrum serine protease plasmin.1 Plasmin, in turn, mediates the pericellular proteolysis of extracellular matrix components and activates other proteases such as matrix metalloproteinases and collagenases that lead to the further degradation and remodeling of the extracellular matrix.2,3
AnaSpec is pleased to introduce two plasminogen activator assay kits – the SensoLyteÒ AFC Urokinase (uPA) Assay Kit and the SensoLyteÒ AMC tPA Assay Kit. These kits, optimized for inhibitor screening, contain high-performance fluorogenic substrates which exhibit high reactivity and low background signal. The AFC (7-amino-4-trifluoromethylcoumarin) labeled substrate in the SensoLyteÒ AFC Urokinase (uPA) Assay Kit can be monitored at Ex/Em= 380/500 nm upon cleavage, with increase in fluorescence correlated to uPA activity. This substrate is not cleaved by tissue-type plasminogen activator (tPA). The AMC (7-amino-4-methylcoumarin) labeled substrate in the SensoLyteÒ AMC tPA Assay Kit can be monitored at Ex/Em=354/442 nm. Upon protease cleavage, this substrate generates the AMC fluorophore emitting bright blue fluorescence. Increase in AMC fluorescence is proportional to tPA activity.
Christman, JK. Research Monographs in Cell and Tissue Physiology, 2. Proteinases in Mammalian Cells and Tissues. AJ. Barett, ed. North Holland Publishing Co. Amsterdam 90-149 (1977).
Duffy, MJ. Curr Pharm Des. 10:39 (2004).
Castellino, FJ. et al. Thromb Haemost. 93:647 (2005).
AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.
AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.
For more information visit www.anaspec.com
Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.
Eurogentec is a privately held company headquartered in Liège, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.
For more information visit www.eurogentec.com